Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTC Biotherapeutics has entered into an extended agreement with PharmAthene, under which GTC will provide continuing process development and clinical supply manufacturing services for PharmAthene's Protexia program.
Subscribe to our email newsletter
The manufacturing work is planned to conclude in the third quarter of 2008. Protexia is being developed by PharmAthene as a pre- and post-exposure therapy for victims of a chemical nerve agent attack.
Geoffrey Cox, GTC’s chairman and CEO, said: “We are pleased to continue to support PharmAthene as it develops Protexia. The constraint in supplying BChE from either human plasma sources or other recombinant systems is an excellent example of transgenic production enabling development of otherwise difficult to express proteins.”